Eli Lilly weight loss drug Zepbound cuts heart failure risks in study

Eli Lilly weight loss drug Zepbound cuts heart failure risks in study

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.  Shelby Knowles | Bloomberg | Getty Images Eli Lilly‘s weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company … Read more

GEHC gives reasons to look beyond temporary China woes and shares reverse higher

GEHC gives reasons to look beyond temporary China woes and shares reverse higher

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue advanced less than 1% year over … Read more

GLP-1s tested for uses beyond weight loss, diabetes

GLP-1s tested for uses beyond weight loss, diabetes

Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The list of potential health benefits from … Read more

Novo Nordisk GLP-1 liraglutide may slow Alzheimer’s progression

Novo Nordisk GLP-1 liraglutide may slow Alzheimer’s progression

A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data … Read more

Roche to accelerate Wegovy weight loss rivals after positive trials

Roche to accelerate Wegovy weight loss rivals after positive trials

Sopa Images | Lightrocket | Getty Images Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company’s two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, … Read more

Biogen Eisai Alzheimer’s drug Leqembi rejected by European regulator

Biogen Eisai Alzheimer’s drug Leqembi rejected by European regulator

European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S.  The European Commission, the EU’s executive body, has a final say in Leqembi’s approval. But it almost always follows the drug regulator’s recommendations.  … Read more

Viking Therapeutics stock jumps on weight loss injection trial plans

Viking Therapeutics stock jumps on weight loss injection trial plans

Weight loss drug concept. Cr | Istock | Getty Images Shares of Viking Therapeutics jumped 16% in premarket trading Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected.  It brings the San Diego-based company one step closer to joining the … Read more

CNBC Daily Open: Rising geopolitical risk

CNBC Daily Open: Rising geopolitical risk

Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City.  Michael M. Santiago | Getty Images This report is from today’s CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no … Read more

Novo Nordisk, Eli Lilly shares slide on Roche’s obesity drug trial

Novo Nordisk, Eli Lilly shares slide on Roche’s obesity drug trial

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate. The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market. Roche shares jumped in … Read more

Ozempic may lower dementia risk, nicotine use

Ozempic may lower dementia risk, nicotine use

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Novo Nordisk‘s blockbuster diabetes drug Ozempic may have more to offer beyond … Read more